Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route), By Region - Industry Forecast 2024-2031

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% in the forecast period (2024-2031).

An increase in infectious diseases is the overall thrust for the vaccine adjuvants market, which is on the rise. Increased incidence of infectious diseases caused by newly and reemerging microbes makes vaccination more effective against these diseases, thereby resulting in increased demand for vaccinations. Hence, adjuvants assume importance in amplifying immunization efficacy as they render shots stronger as well as a robust defense against infections. For instance, more attention is being given to the aspect of immunization as a primary route to preventing diseases in this upward trend in preventive care all over the world, especially in the wake of the COVID-19 pandemic. This can be attributed to the fact that there is a push towards preventive health care. The immune system identifies certain molecules as alien bodies and attacks them. The molecules referred to here are known as antigens. The adjuvants could provide persistence of the antigen at the injection site, activate the cells of immunity, and modulate the immune response to stimulate a more potent and prolonged response in other ways of stimulation of the immune system. The advancements in R&D in vaccination led to an accumulation of a larger number of innovative vaccines targeting various diseases meant for curing. More vaccine candidates are currently being developed, thereby increasing the demand for adjuvants to enhance the efficacy of vaccines. The market opportunity for vaccine adjuvants is thus expanding.